Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Vivani Medical ( (VANI) ) has issued an announcement.
On October 3, 2025, Vivani Medical announced the temporary withdrawal of the record date for the spin-off of its subsidiary, Cortigent, Inc., due to delays from the U.S. federal government shutdown. Cortigent, which develops brain implant devices with neuromodulation technology, is expected to have a new record date announced soon, with ThinkEquity acting as the exclusive financial advisor for the transaction.
The most recent analyst rating on (VANI) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Vivani Medical stock, see the VANI Stock Forecast page.
Spark’s Take on VANI Stock
According to Spark, TipRanks’ AI Analyst, VANI is a Neutral.
Vivani Medical’s overall score reflects its challenging financial situation and unfavorable valuation. Despite some positive corporate events and neutral technical indicators, the company’s consistent losses and reliance on external financing weigh heavily on the score. The strategic focus on core drug implant business and recent milestones offer some potential for improvement, but substantial operational and financial efficiency improvements are necessary for a stronger outlook.
To see Spark’s full report on VANI stock, click here.
More about Vivani Medical
Vivani Medical, Inc. is a clinical-stage biopharmaceutical company that develops miniature, ultra long-acting drug implants using its proprietary NanoPortal™ platform. These implants are designed to deliver drug molecules steadily over extended periods, aiming to improve medication adherence and patient tolerance. Vivani focuses on developing GLP-1 based implants for metabolic diseases such as obesity and type 2 diabetes.
Average Trading Volume: 147,858
Technical Sentiment Signal: Buy
Current Market Cap: $85.31M
For a thorough assessment of VANI stock, go to TipRanks’ Stock Analysis page.